Retatrutide might be one of the biggest metabolic health breakthroughs of our lifetime.
Eli Lilly’s Phase 3 TRIUMPH-1 results are hard to ignore:
- 28.3% average bodyweight loss on 12mg over 80 weeks.
- 45.3% of patients hit 30% weight loss.
- Higher-BMI patients continued to lose up to 30.3% over 104 weeks.
That is not “a little weight loss.”
That is potentially life-changing.
And I don’t say that lightly. I’ve seen people close to me benefit hugely from GLP-1s and next-generation peptide therapies. More energy. Better habits. Better blood markers. A completely different relationship with their own health.
But the exciting part is also the scary part.
We are moving faster than our long-term knowledge.
Retatrutide targets GLP-1, GIP, and glucagon, which is why the results look so powerful. But with any new therapy, especially one that could be used by millions of people, tracking matters.
Side effects matter.
Dose changes matter.
Sleep, heart rate, blood pressure, appetite, mood, labs, training, nutrition, all of it matters.
This is one of the reasons we’re building PeptideTrack.
Not to hype peptides blindly.
But to help people stop guessing.
The next decade of metabolic health will not just be about access to powerful medications.
It will be about using them responsibly, tracking real outcomes, and learning from the data.
Retatrutide could genuinely change millions of lives.
Now we need the tools, education, and discipline to make sure people use it safely.
#Retatrutide #Peptides #EliLilly